This is the authors' abstract. We don't add key points for this paper.
The many thousands of people living with cystic fibrosis are at a greater risk of developing a chronic lung infection caused by Mycobacterium abscessus. Since M. abscessus is clinically resistant to most anti-TB drugs available, treatment options are limited to macrolides. Despite macrolide-based therapies, cure rates for M. abscessus lung infections are 50%. Using an in-house library of curated natural products, we identified lysobactin and sorangicin A as novel scaffolds for the future development of antimicrobials for patients with M. abscessus infections.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sullivan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: